ArticleBlood advances2020

Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms.

Michael A Spinner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.